Prediction of Survival in Diffuse Large B Cell Lymphoma According to Immunohistochemistry

Viola Cavolli; Borce Georgievski

doi:10.3889/oamjms.2023.11775

Authors

Viola Cavolli Department of Hematology, University Clinic Centre of Kosovo, Prishtina, Kosovo; Doctoral student, Medical Faculty, Ss Cyril and Methodius University, Skopje, Macedonia https://orcid.org/0000-0002-9271-2915
Borce Georgievski Department of Hematology, Medical Faculty, Ss Cyril and Methodius University, Skopje, Macedonia

DOI:

https://doi.org/10.3889/oamjms.2023.11775

Keywords:

Germinal center B cell-like group, non-Germinal center B cell-like group, double positive, triple negative, PFS, OS

Abstract

BACKGROUND: The introduction of chemoimmunotherapy in the treatment of diffuse large B cell lymphoma (DLBCL) dramatically improved the outcomes compared to chemotherapy alone. However, a significant part of the patients become refractory and eventually relapse.

AIM: The purpose of this study is to analyze the survival differences between different groups of DLBCL according to Han’s algorithm.

MATERIALS AND METHODS: We will study the medical records of 244 patients treated with RCHOP as first-line therapy who are diagnosed with de novo DLBCL in a cohort of 10 years in the University Clinical Center of Kosovo. According to immunohistochemical markers, the patients will be classified into two major groups, germinal center B cell-like (GCB) and non-germinal center B cell-like (non-GCB) subtypes, and five subgroups (Group 1, Group 2, Group 3 or double positive, Group 4, and Group 5 or triple negative [TN]).

RESULTS: The patients in the GCB group have better progression-free survival (PFS) and overall survival (OS) than the non-GCB group. Despite this, double positive (DP) (CD10+MUM1+) and TN (CD10−Bcl6−MUM−) subgroups showed different PFS and OS to the same cell-of-origin group. The DP group showed similar OS and PFS with the non-GCB group, whereas the TN group showed similar OS and PFS with the GCB group.

CONCLUSION: These factors will provide valuable knowledge for predicting the prognosis and redirecting the choice of treatment for different groups of DLBCL.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375- 90. https://doi.org/10.1182/blood-2016-01-643569 PMid:26980727

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-76. https://doi.org/10.1182/blood-2005-06-2508 PMid:16150940

Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood. 2010;116(19):3724- 34. https://doi.org/10.1182/blood-2010-05-282632 PMid:20664057

Morgensztern D, Martin MG, Lossos IS. Gene expression profiling in diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48(4):669-82. https://doi.org/10.1080/10428190601186176 PMid:17454624

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11. https://doi.org/10.1038/35000501 PMid:10676951

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. Lymphoma/leukemia molecular profiling project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47. https://doi.org/10.1056/NEJMoa012914 PMid:12075054

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183- 90. https://doi.org/10.1182/blood-2005-04-1399 PMid:16046532

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82. https://doi.org/10.1182/blood-2003-05-1545 PMid:14504078

Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617-29. https://doi.org/10.1002/ajh.26151 PMid:33661537

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-80. https://doi.org/10.1200/JCO.2009.26.2493 PMid:20385988

Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135(16):1396-405. https://doi.org/10.1182/blood.2019003526 PMid:31978225

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AF, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845-53. https://doi.org/10.1200/JCO.2018.78.5246 PMid:30125215

Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood. 2009;114(11):2273-9. https://doi.org/10.1182/blood-2009-03-212191 PMid:19597184

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378(15):1396-407. https://doi.org/10.1056/NEJMoa1801445 PMid:29641966

Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-13. https://doi.org/10.1038/leu.2012.83 PMid:22437443

Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-7. https://doi.org/10.1200/JCO.2010.30.0368 PMid:21135273

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppä S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol. 2009;22(8):1094-101. https://doi.org/10.1038/modpathol.2009.73 PMid:19448593

Gutiérrez-García G, Cardesa-Salzmann T, Climent F, González- Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836-43. https://doi.org/10.1182/blood-2010-12-322362 PMid:21441466

Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109(11):4930-5. https://doi.org/10.1182/blood-2006-09-047068 PMid:17299093

Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117(26):7070-8. https://doi.org/10.1182/blood-2011-04-345256 PMid:21536860

Chavez J, Walsh M, Hernandez-Ilizaliturri FJ, Elefante A, Czuczman MS. Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han’s criteria defines two groups of patients with different clinical outcomes following systemic rituximab-multi agent anthracycline-based therapy. Blood. 2009;114(22):623.

Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-94. https://doi.org/10.1200/JCO.2007.15.9277 PMid:18662967

Lu TX, Miao Y, Wu JZ, Gong QX, Liang JH, Wang Z, et al. The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma. Sci Rep. 2016;6:20465. https://doi.org/10.1038/srep20465 PMid:26857366

Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28(4):464-70. https://doi.org/10.1097/00000478-200404000-00005 PMid:15087665

Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78-84. https://doi.org/10.1182/blood-2002-04-1286 PMid:12393466

Coutinho R, Clear AJ, Owen A, Wilson A, Matthews J, Lee A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: Implications for therapeutic strategies. Clin Cancer Res. 2013;19(24):6686-95. https://doi.org/10.1158/1078-0432.CCR-13-1482 PMid:24122791

Hwang HS, Park CS, Yoon DH, Suh C, Huh J. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol. 2014;38(8):1046-57. https://doi.org/10.1097/PAS.0000000000000211 PMid:24705314

Benesova K, Forsterova K, Votavova H, Campr V, Stritesky J, Velenska Z, et al. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma. 2013;60(1):68-73. https://doi.org/10.4149/neo_2013_010 PMid:23067219

Gu K, Weisenburger DD, Fu K, Chan WC, Greiner TC, Aoun P, et al. Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. Hematol Oncol. 2012;30(3):143-9. https://doi.org/10.1002/hon.1017 PMid:22009820